COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00276796
Recruitment Status : Completed
First Posted : January 13, 2006
Last Update Posted : May 27, 2013
National Cancer Institute (NCI)
Information provided by:
Gynecologic Oncology Group

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, topotecan, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving paclitaxel together with topotecan and cisplatin works in treating patients with advanced, persistent, or recurrent cervical cancer.

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: cisplatin Drug: paclitaxel Drug: topotecan hydrochloride Phase 2

Detailed Description:



  • Estimate the antitumor activity of the combination of paclitaxel, topotecan, and cisplatin in patients with advanced, persistent, or recurrent carcinoma of the cervix.
  • Determine the nature and degree of toxicity for this drug regimen in these patients.


  • Determine the duration of progression-free survival and overall survival.
  • Determine the impact of prior chemoradiation on response to treatment.

OUTLINE: This is an open-label study.

Patients receive paclitaxel IV over 1 hour followed by topotecan IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 66 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Actual Primary Completion Date : January 2007

Primary Outcome Measures :
  1. The frequency and duration of objective response
  2. The frequency and severity of observed adverse effects

Secondary Outcome Measures :
  1. Progression-free survival and overall survival
  2. Prognostic factor: prior chemoradiation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Advanced, persistent, or recurrent squamous or nonsquamous cell carcinoma of the cervix with documented disease progression

    • Histologic confirmation of the original primary tumor is required
  • Disease must be measurable in at least one dimension by conventional techniques, including palpation, plain x-ray, CT scan, or MRI

    • Measurable disease is defined as at least one lesion that can be accurately measured
    • Each lesion must be ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
    • Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence ≥ 90 days after completion of radiation therapy


  • GOG performance status 0-2
  • Platelet count ≥ 100,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Creatinine ≤ 1.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • SGOT and alkaline phosphatase ≤ 2.5 times ULN
  • Neuropathy (sensory and motor) ≤ grade 1
  • No active infection requiring antibiotics
  • No evidence of more than one malignancy present within the past 5 years

    • Nonmelanoma skin cancer allowed
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


  • No prior therapy with cytotoxic drugs for advanced or recurrent cervical carcinoma

    • Prior cisplatin as a radiosensitizer for primary treatment of disease allowed
  • No previous cancer treatment that contraindicates study treatment
  • No prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of cervical cancer
  • No prior chemotherapy for any abdominal or pelvic tumor except for the treatment of cervical cancer
  • Recovered from effects of recent surgery, radiotherapy, or other therapy
  • At least 4 weeks since prior radiotherapy
  • More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin and free of recurrent or metastatic disease
  • More than 3 years since prior adjuvant chemotherapy for localized breast cancer provided patient is free of recurrent or metastatic disease
  • No hormonal therapy directed at the malignant tumor within the past week
  • Concurrent hormone replacement therapy is permitted
  • No concurrent amifostine or other protective reagents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00276796

Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Harry J. Long, MD Mayo Clinic
Layout table for additonal information
Responsible Party: Philip J. DiSaia, Gynecologic Oncology Group Identifier: NCT00276796    
Other Study ID Numbers: CDR0000456248
First Posted: January 13, 2006    Key Record Dates
Last Update Posted: May 27, 2013
Last Verified: February 2009
Keywords provided by Gynecologic Oncology Group:
cervical squamous cell carcinoma
stage III cervical cancer
recurrent cervical cancer
cervical adenocarcinoma
cervical adenosquamous cell carcinoma
cervical small cell carcinoma
stage IVA cervical cancer
stage IVB cervical cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors